Effects of cimetidine and ranitidine on the pharmacokinetics of quinine

British Journal of Clinical Pharmacology
S WanwimolrukP Patamasucon

Abstract

The pharmacokinetics of orally administered quinine were determined in six normal volunteers before and after a 7-day course of cimetidine (1 g day-1) or ranitidine (300 mg day-1). Peak plasma quinine concentration and the time of peak concentration were not altered after cimetidine or ranitidine pretreatment. After cimetidine pretreatment there was a significant reduction in the apparent oral clearance of quinine, from 0.182 +/- 0.063 (mean +/- s.d.) to 0.133 +/- 0.055 1 h-1 kg-1 (P less than 0.05). This was reflected in a 49% (range 17 to 90%) increase in the mean elimination half-life from 7.6 +/- 1.3 to 11.3 +/- 3.7 h (P less than 0.05). In contrast to cimetidine, ranitidine had no significant effect on the clearance or half-life of quinine. The apparent interaction between quinine and cimetidine may have therapeutic implications. Special care should be taken in patients taking these two common drugs concomitantly. Additionally, to avoid unnecessary risks due to drug interaction, the use of ranitidine may be preferable in the patients in whom it is desirable to administer an H2-receptor antagonist together with quinine.

References

Apr 1, 1976·Clinical Pharmacology and Therapeutics·G M TrenholmeP E Carson
Oct 1, 1975·Clinical Pharmacology and Therapeutics·G R Wilkinson, D G Shand
May 1, 1985·Clinical Pharmacokinetics·N J White
Apr 1, 1973·Journal of Pharmacokinetics and Biopharmaceutics·M RowlandG G Graham
Nov 1, 1984·Clinical Pharmacokinetics·W KirchH D Janisch
Sep 1, 1983·Clinical Pharmacokinetics·E S Vesell, M B Penno
Jan 1, 1984·Therapeutic Drug Monitoring·K W KolbT Fox
Oct 1, 1983·British Journal of Clinical Pharmacology·N J WhiteK Silamut
Jul 1, 1983·The American Journal of Cardiology·B G HardyJ J Schentag
Mar 1, 1980·Clinical Pharmacokinetics·H R OchsE Woo
Jan 1, 1982·Clinical Pharmacokinetics·A Somogyi, R Gugler

❮ Previous
Next ❯

Citations

Jul 1, 1990·Journal of Clinical Pharmacology·R E SmallW J Adams
Jan 1, 1987·Pharmacology & Therapeutics·M MitchardB M Mullinger
Jan 1, 1991·Pharmacology & Therapeutics·U Klotz, H K Kroemer

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.